Ronit Capital’s Pfizer PFE Stock Holding History

Ronit Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,000	Closed	-$181K	–	68
2021 Q1	$181K	Sell	5,000 -4,000	-44%	-$142K	0.11%	46
2020 Q4	$331K	Buy	+9,000	New	+$330K	0.19%	39

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ronit Capital's PFE Position: Q2 2021 in Review

Ronit Capital sold out of Pfizer (PFE) in Q2 2021, closing a stake of 5,000 shares — an estimated $181K sold.

Ronit Capital first reported a position in PFE in Q4 2020 and held it in 2 quarters. The position peaked at $331K in Q4 2020. 2,733 funds tracked by Wall St. Rank hold PFE as of Q2 2021.

Ronit Capital reported no remaining Pfizer position as of Q2 2021 after selling out during the quarter.
Ronit Capital sold 5,000 Pfizer shares in Q2 2021, an estimated $181K.
Ronit Capital first reported a position in Pfizer in Q4 2020 and held it in 2 quarters.
Ronit Capital's Pfizer position peaked at $331K in Q4 2020.
2,733 funds tracked by Wall St. Rank held Pfizer as of Q2 2021.

Based on Ronit Capital's 13F filing for Q2 2021, filed 5 Aug 2021.